logo-loader
viewAldeyra Therapeutics

Aldeyra Therapeutics reports positive results from a phase 2a trial of its treatment for dry eye disease

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement

Dry eye treatment
The group said it now expects to initiate a phase 2b trial in the first half of 2018

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) saw its shares soar over 50% higher in premarket trade after the biotechnology company reported positive results from a phase 2a trial of its treatment for dry eye disease.

In a statement, the Nasdaq-listed company said that based on statistically and clinically significant activity across a number of sign and symptom endpoints and tolerability, the ADX-102 treatment was nominated for advancement.

The group said it now expects to initiate a phase 2b trial in the first half of 2018.

Aldeyra’s chief executive Todd Brady said: “These data represent the fourth set of positive phase 2 results with ADX-102 in ocular inflammation.

"The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology."

In reaction to the news, Aldeyra shares were up 52.38%, putting them on track to open at the highest level seen in over nine months.

Quick facts: Aldeyra Therapeutics

Price: 5.12 USD

NASDAQ:ALDX
Market: NASDAQ
Market Cap: $143.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator's Stephen Blyth outlines five-year growth plans as core businesses...

Xpediator PLC's (LON:XPD) Stephen Blyth speaks to Proactive London following the release of its 2019 trading update. The firm saw turnover rise 19% to £212mln - boosted by acquisitions and organic growth while adjusted pre-tax profit's expected to be slightly above £5mln. Blyth says a big...

2 days, 16 hours ago

2 min read